(Credit-Canva)
The current measles outbreak has gripped US states like Texas and New Mexico leaving people worried whether it would become a new pandemic. According to the Texas Department of State Health Services as of February 21, 90 cases were diagnosed in the last month in the South Plains area, with at least 77 of them were reported in children and teens under 17.
Measles is highly contagious and can be deadly. The outbreak, which started spreading in late January, has resulted in multiple hospitalizations, with at least nine confirmed cases and three probable cases as of early February. Health officials caution that at least one in five infected individuals will have to be hospitalized, highlighting the severity of the situation.
Misinformation surrounding vaccines and with the new Trump administration anti-vaccine campaigs, has causing parents to hesitate or refuse vaccination.
Furthermore, the country down under Australia is also witnessing a surge in measles cases as health officials in Sydney have issued an urgent alert, urging residents to watch for measles symptoms after an infected individual visited several places in Sydney over the last seven days.
Authorities report that the traveller had returned from South East Asia where there are ongoing outbreaks of measles.
Key symptoms of measles include fever, a runny nose, sore eyes, and a cough. Typically, a red, blotchy rash appears three to four days later, spreading from the head down to the body. Symptoms can manifest between 7 and 18 days after exposure.
Anyone who experiences these symptoms after potential exposure should immediately contact their doctor or emergency department. It is crucial to call ahead before visiting to avoid potentially exposing others in the waiting room. Dr. Selvey also highlighted that ongoing measles outbreaks are occurring in various parts of the world, making awareness and prompt action essential.
According to CDC everyone should get the MMR vaccine. It protects you from measles, mumps, and rubella. Getting vaccinated helps stop these diseases from spreading. There are two safe MMR vaccines available. They work the same way, so it doesn't matter which one you get. Kids can also get a shot that protects against chickenpox too, but this is only for children.
All children should get two MMR shots. The first shot should be given when they are between 12 and 15 months old. The second shot should be given when they are between 4 and 6 years old. If needed, the second shot can be given earlier, but it must be at least 28 days after the first shot.
Students going to college or other schools after high school, need two shots if they are not already immune. The shots must be at least 28 days apart.
Most adults need at least one MMR shot. Some adults need two shots, especially those who work in healthcare, travel a lot, or go to college. These people should get two shots, with 28 days between them.
Anyone traveling to other countries should make sure they are protected. Babies 6 to 11 months old should get one shot before traveling. Kids 12 months and older, teens, and adults need two shots, with 28 days between them.
People who work in healthcare should have proof that they are immune to measles, mumps, and rubella. If they are not immune, they need two MMR shots, spaced 28 days apart.
Women who might get pregnant should talk to their doctor about the MMR vaccine. It's safe to get the shot while breastfeeding.
Credit: iStock
Takeda Biopharmaceuticals India today announced that QDENGA (TAK-003) has become the first dengue vaccine to receive approval in India, marking a major milestone in the country's fight against the mosquito-borne disease.
The Drug Controller General of India (DCGI) has granted market authorization for QDENGA to prevent dengue in individuals aged 4-60 years. According to Takeda, it is India's first approved dengue vaccine and can be administered regardless of previous dengue infection, without requiring pre-vaccination testing.
"Since its launch in 2022, QDENGA has been approved in 43 countries, with more than 32 million doses distributed globally. This approval marks an important step forward in strengthening dengue prevention in India," said Dr. Mahender Nayak, Head of Intercontinental Markets.
The approval comes at a critical time as dengue cases in India have risen sharply over the past two decades.
India accounts for nearly one-third of the global dengue burden. In 2025, more than 113,000 dengue cases were officially reported, although modelling studies suggest the true number of infections may run into tens of millions annually due to underreporting.
Rapid urbanization, climate change and widespread mosquito breeding have made dengue a year-round public health concern. Since there is no specific antiviral treatment for dengue, prevention remains the most effective strategy.
"India carries a substantial dengue burden, and all four dengue virus serotypes co-circulate in several regions. QDENGA is designed to protect against all four serotypes regardless of prior exposure," said Dr. Goh Choo Beng, Medical Affairs Head, Southeast Asia & India Cluster.
The DCGI approval is supported by Takeda's global clinical development programme comprising 19 Phase 1, 2 and 3 clinical trials involving more than 28,000 participants in dengue-endemic and non-endemic regions.
The pivotal Phase III TIDES (DEN-301) study enrolled more than 20,000 participants across eight countries and evaluated the vaccine's long-term safety and effectiveness.
Key findings include:
The approval is also supported by an Indian Phase III (DEN-302) trial involving participants aged 4-60 years, which found QDENGA to be safe, well-tolerated and immunogenic in children, adolescents and adults.
QDENGA (TAK-003) is a live-attenuated tetravalent dengue vaccine designed to protect against all four dengue virus serotypes.
It is administered as two 0.5 mL subcutaneous doses, given three months apart.
The vaccine is built on a DENV-2 backbone, incorporating structural proteins from DENV-1, DENV-3 and DENV-4 to provide broad immune protection.
The World Health Organization (WHO) recommends QDENGA for use in dengue-endemic settings without the need for pre-vaccination screening. The vaccine is also included in the WHO List of Prequalified Vaccines, allowing procurement through agencies such as UNICEF and PAHO.
The vaccine has been approved in 43 countries across Asia, Latin America and Europe. It is already part of Brazil's National Immunization Program and is available through public immunization programmes in Argentina, Colombia and Indonesia.
The vaccine is approved in India for people aged 4-60 years to help prevent dengue disease.
Takeda had partnered with Indian vaccine manufacturer Biological E in 2024 to expand production of QDENGA.
Under the agreement, Biological E plans to manufacture 50 million doses annually, supporting Takeda's goal of producing 100 million doses globally each year by the end of the decade.
Credit: iStock
COVID-19 is seeing a renewed uptick in India, with 339 infections reported between July 1 and July 16, according to the Andhra Pradesh Health Department.
Andhra Pradesh has reported four COVID-related deaths and 19 active cases, prompting heightened surveillance after officials identified the Omicron RF.5 sublineage in infected patients in the state.
The presence of RF.5 sublineage in Andhra was confirmed through genome sequencing of patient samples from YSR Kadapa district at the National Institute of Virology (NIV), Pune.
According to the Andhra Pradesh Health Department states that reported COVID infections fromJuly 1-16 include:
RF.5 is an Omicron sublineage identified through genome sequencing. The World Health Organization (WHO) is monitoring the variant after it was reported in higher numbers in Singapore and other parts of Southeast Asia, prompting Indian health authorities to closely track its spread.
According to the Andhra Pradesh government, RF.5 evolved naturally from the Omicron JN.1 lineage through the LF.7 and PY.1.1.1 sublineages.
Officials said it is not a recombinant variant, meaning it evolved within a single genetic lineage rather than through the combination of two different variants.
Based on current evidence, Dr. Vishnuvardhan said there is no indication that RF.5 causes more severe disease than other Omicron subvariants currently in circulation, although continued surveillance remains important.
The symptoms of RF.5 are similar to those seen with other Omicron variants and include:
In a post on X, Dr. Vipin M. Vashishtha, Member of the WHO Vaccine Safety Net (VSN), said RF.5 carries several spike mutations that may influence how the virus behaves:
However, Dr. Vashishtha said these mutations alone should not be considered reliable predictors of disease severity. RF.5 continues to be monitored through WHO genomic surveillance.
According to health officials, there is currently no cause for alarm.
Health officials advise people to:
Credit: iStock
Amid the ongoing Cyclospora parasite outbreak linked to lettuce supplied by Taylor Farms, the produce company has recalled shredded iceberg lettuce distributed across 27 US states over possible contamination concerns.
The outbreak, which has been under investigation for more than a month, has sickened over 5,000 people across at least 34 states, causing widespread cases of diarrhea.
The Centers for Disease Control and Prevention (CDC) initially linked the outbreak to lettuce supplied by Taylor Farms to Taco Bell restaurants in five states earlier this week. However, a recall notice issued by the company late last week indicated that the potentially contaminated lettuce had a much wider distribution.
Taylor Farms said it is "actively removing" the affected products, has suspended distribution of iceberg lettuce imported from Central Mexico to the United States, and is no longer receiving products from the implicated lot.
"Consumers who have purchased the recalled iceberg lettuce should discard it immediately and not consume it," the company said.
Also read: Cyclospora Parasite Outbreak: Why You Should Avoid Packaged Salads and Go For Loose Greens
According to Taylor Farms, the recalled shredded iceberg lettuce was distributed between June 29 and July 16 in:
Alabama, Arkansas, Connecticut, Florida, Georgia, Iowa, Illinois, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Maryland, Michigan, Missouri, Mississippi, North Carolina, New Hampshire, New Jersey, Ohio, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Virginia and Wisconsin.
The recall notice includes product descriptions, brand abbreviations and use-by dates but does not identify specific retailers, restaurants or product names.
"At this time, Taylor Fresh Foods has not publicly provided distribution information or a list of customers who received the product that was voluntarily removed from the market," the US Food and Drug Administration (FDA) said.
The FDA also noted that an earlier lettuce sample from Taylor Farms initially tested positive for Cyclospora but later determined the result "should be considered a false positive."
"FDA and state partners continue to collect and analyze product samples," the agency said, adding that no confirmed positive samples have been identified so far.
Taylor Farms also said on social media that none of its Taylor Farms-branded salad kits are associated with the outbreak. Most of the recalled lettuce was sold in large bags to food-service operations, including restaurants, with many products blended with romaine lettuce.
Further, media reports stated that several companies have begun removing affected products from stores and supply chains.
The list includes
Food safety experts said that additional distributors and restaurants may also have received the recalled lettuce, even if they have not publicly disclosed it.
The FDA said Taylor Farms "has not publicly provided distribution information or a list of customers who received the product that was voluntarily removed from the market." Current FDA regulations do not require companies to disclose that information.
Sandra B. Eskin, chief executive of Stop Foodborne Illness, said the lack of transparency can limit the effectiveness of recalls. She added, "The whole point is to quickly identify the product and make sure no one else eats it."
Health officials recommend:
Experts also recommend choosing whole heads of lettuce instead of bagged greens. Remove the outer leaves, wash the inner leaves thoroughly under running water, and cook produce whenever possible, as heat is the most effective way to kill Cyclospora.
© 2024 Bennett, Coleman & Company Limited